Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.

Firms / Dcvc Bio

Dcvc Bio

Multi-stage venture firmPalo Alto, CAdcvc.comSEC venture capital fund adviserpart of DCVC

One of 2 advisers that share dcvc.com; the firm is DCVC. Dcvc. Each keeps its own CRD, funds and filings; the grouping is the website each swore to on Form ADV and is recomputed every pass.

both early and growth/opportunity families, reported GAV $1,198M

Importance
32
moderate
Active deployment
29
moderate
Emerging
0
low
Completeness
63
high
Freshness
99
high
Research priority
13
low
Identity and regulatory footprint
Headquarters
Palo Alto, CAadviserinfo.sec.gov
Office address
270 UNIVERSITY AVENUE, Palo Alto, CA, 94301adviserinfo.sec.gov
Business phone
415-840-7337adviserinfo.sec.gov
SEC adviser type
exempt reporting adviseradviserinfo.sec.gov
SEC exemption claimed
venture capital fund adviseradviserinfo.sec.govItem 2.B(1): advises solely venture capital funds
Latest Form ADV
Mar 31, 2026
Private funds reported
4 (4 venture capital funds)adviserinfo.sec.gov
Private fund gross assets
$1.0Badviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
Owners on Schedule A
ZNM Capital Management, LLC (Member), D; JNK Capital Management, LLC (Member), D
business phone
415-840-7337adviserinfo.sec.govpublished by the subject
Stated thesis versus observed behaviour
1 observed deals
Stated (the firm’s website)
Sectors
not stated or not yet read
Stages
not stated or not yet read
Geography
not stated
Check size
not stated; DFX does not estimate checks from round sizes
Observed (from deals on record)
Stage at participation
series b 100%
Stage at first entry
series b 100%
Sectors
Agriculture 100%
lead rate 0%follow-on rate 0%new logos, 12 months 1
Funds and vehicles
4 reported
VehicleTypeVintageLifecycleReported GAVOwnersForm D soldLatest Form D
Dcvc Bio III, L.P.Fund2024 adv first reportedEarly deployment$339M
Mar 29, 2024
31$0
of $400M
Sep 28, 2023
Dcvc Bio Opportunity Fund, L.P.Opportunity fund2022 adv first reportedActive deployment$190M
Mar 29, 2024
34$0
of $350M
Nov 18, 2021
Dcvc Bio II, L.P.Fund2020 form d first saleMature$341M
Mar 29, 2024
33$350M
of $350M
Aug 4, 2020
Dcvc Bio, L.P.Fund2018 form d first saleHarvest$328M
Mar 29, 2024
41$208M
of $250M
May 14, 2019
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
13 current, 2 departed
Ryan T Ward
Chief Legal Officer · since Sep 1, 2022
Platform and operations
2 departed (kept with end dates)
Investments on record
1 edges, 1 companies, 1 partner-attributed
CompanyRoundRolePartnerRound sizeThis investorDateSource
AgZenSeries B · Series BparticipantJustin Kern (confirmed)$10.0MunknownMar 13, 2026Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)
“This investor” is the amount disclosed for this investor alone; it is unknown unless a source said it. The round size is the whole round.
Co-investors
40 relationships from shared deals, counted for the whole firm
Institutional Venture 3 shared · recurring137 Ventures Management, LLC 3 shared · recurringNightdragon Management Company, LLC 3 shared · recurringKhosla Ventures, LLC 3 shared · recurringInnovation Endeavors: Reimagining the technical frontier 2 shared · recurringGreat Oaks Management Company LLC 2 shared · recurringCanaan Partners 2 shared · recurringMadrona Venture Group, LLC 2 shared · recurringGlynn Capital Management, LLC 2 shared · recurringPrime Movers Lab LLC 2 shared · recurringWebb Investment Network Management, LLC 2 shared · recurringBlackbird Ventures Pty Ltd. 2 shared · recurringIcon Ventures 2 shared · recurringTenoneten 2 shared · recurringSpider Capital 2 shared · recurringDorm Room Fund 2 shared · recurringSapphire Ventures, LLC 2 shared · recurringLUX Capital Management, LLC 2 shared · recurringBling Capital LLC 2 shared · recurringAIM Master I (bvi) Ltd. 2 shared · recurringEthos Manager LLC 2 shared · recurringEmergence Equity Management, Inc 2 shared · recurringPascal Capital, L.L.C. 2 shared · recurringEpsilon Health Investors, LLC 1 shared · one timeAlpha Partners Management, LLC 1 shared · one timeHuman Capital 1 shared · one timeMPM Bioimpact 1 shared · one timeCollaborative Fund Management LLC 1 shared · one timeCompound Advisors, LLC 1 shared · one timeIselect Fund Management, LLC 1 shared · one timePillar Companies Management, LLC 1 shared · one timeBoot64 Ventures LLC 1 shared · one timeQuest Venture Partners 1 shared · one timeMaterial Impact Management, LLC 1 shared · one timeIA Capital Group, Inc. 1 shared · one timeInvivium Capital 1 shared · one timeMillennium Technology Value Partners 1 shared · one timeRadical Ventures 1 shared · one timeLeap Global Partners 1 shared · one timeHOF Capital 1 shared · one time
Limited partners
0 disclosed
No LP commitment on record. An LP edge needs a public disclosure with a quote: a pension report (see Limited partners for the plans read), a fund announcement naming the LP, or a Form ADV owner. The fund page carries the LP’s reported performance.
Timeline
10 dated events
  1. Sep 15, 2026
    Dcvc Bio: INSTITUTIONAL_VC -> MULTI_STAGE_VC (both early and growth/opportunity families, reported GAV $1,198M)
    Classification changedClassificationInferenceno URL
  2. Mar 29, 2024
    Dcvc Bio III, L.P. first reported on Form ADV by Dcvc Bio (Venture Capital Fund), GAV $338,504,267
  3. Mar 31, 2023
    Scott James (General Counsel) no longer on Schedule A of Dcvc Bio
  4. Sep 1, 2022
    Ryan T Ward joined Schedule A of Dcvc Bio as Chief Legal Officer
  5. Mar 29, 2022
    Dcvc Bio Opportunity Fund, L.P. first reported on Form ADV by Dcvc Bio (Venture Capital Fund), GAV $165,668,056
  6. Apr 1, 2021
    Dcvc Bio II, L.P. first reported on Form ADV by Dcvc Bio (Venture Capital Fund), GAV $351,157,922
  7. Mar 29, 2019
    Jocelyn Marie Serrescooke (Chief Financial Officer) no longer on Schedule A of Dcvc Bio Management Co, LLC
  8. Aug 1, 2018
    Scott James joined Schedule A of Dcvc Bio Management Co, LLC as General Counsel
  9. Jun 19, 2018
    Dcvc Bio Management Co, LLC first filed Form ADV (ERA, venture capital fund adviser exemption)
  10. Jun 19, 2018
    Dcvc Bio, L.P. first reported on Form ADV by Dcvc Bio Management Co, LLC (Venture Capital Fund), GAV $75,300,000
Classification history
  1. Sep 15, 2026
    Multi-stage venture firm (confirmed, 95%, cls-1)
    both early and growth/opportunity families, reported GAV $1,198M
  2. Sep 12, 2026
    Institutional venture firm (confirmed, 95%, cls-1)
    venture manager, reported GAV $857M across 3 vehicles
Evidence
37 observations from 3 sources
Every observation behind this profile, with its source, date and class
FactValueEffectiveClassSource
Why admittedvc_exemption,vc_funds_reportedMar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
SEC exemption claimedventure_capital_fund_adviserMar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
SEC exemption claimedventure_capital_fund_adviserMar 29, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
SEC adviser typeexempt_reporting_adviserMar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
SEC adviser typeexempt_reporting_adviserMar 29, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
First Form ADV filing2018-06-19Mar 29, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Adv history loadedadv-hist-1Sep 12, 2026FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Latest Form ADV filing2026-03-31Mar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Latest Form ADV filing2024-03-29Mar 29, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
SEC statusERA - ActiveMar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
SEC status effective2018-06-19Mar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Venture share of reported funds1Mar 29, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Business phone415-840-7337Mar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Business phone415-840-7337Mar 29, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
HeadquartersPalo Alto, CAMar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
HeadquartersPalo Alto, CAMar 29, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Office address270 UNIVERSITY AVENUE, Palo Alto, CA, 94301Mar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Office address270 UNIVERSITY AVENUE, Palo Alto, CA, 94301Mar 29, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Legal formLimited Liability CompanyMar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Legal formLimited Liability CompanyMar 29, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Private funds reported4Mar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Private funds reported4Mar 29, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Private fund gross assets (reported)$1.0BMar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Private fund gross assets (reported)$1.2BMar 29, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Schedule a diffsadiff-1Mar 31, 2026FactIAPD Form ADV Part 1 PDF per firm (current filing, Schedule D 7.B.(1) and Schedule A)
Venture funds reported4Mar 31, 2026FactSEC Form ADV monthly roster (registered + exempt reporting advisers)
Venture funds reported4Mar 29, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Websitehttp://www.dcvc.comMar 29, 2024FactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)